Federal Register / Vol. 72, No. 89 / Wednesday, May 9, 2007 / Notices 26413 

Dated: May 2, 2007. 

Judith Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2299 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of Licensee’s proprietary 

delivery formulation containing 

synthetic peptides of the CEA antigen 

(or modifications, derivatives, 

fragments, or immunogenic epitopes 

thereof) as claimed in the Licensed 

Patent Rights, alone or in combination 

with at least one other synthetic 

peptide for use in the prevention and/ 

or treatment of adenocarcinomas in 

humans. For the avoidance of doubt, 

said delivery formulation specifically 

excludes all poxviruses, eukaryotic 

expression vectors, and recombinant 

yeast 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent 6,756,038 and 

PCT Application Serial No. PCT/US98/ 

19794 and foreign equivalents thereof, 

entitled ‘‘Agonist and Antagonist 

Peptides of Carcinoembryonic Antigen 

(CEA)’’ (E–099–1996/0), to Immatics 

Biotechnologies, GmbH, which is 

located in Tuebingen, Germany. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the use 

of Licensee’s proprietary delivery 

formulation containing synthetic 

peptides of the CEA antigen (or 

modifications, derivatives, fragments, or 

immunogenic epitopes thereof) as 

claimed in the Licensed Patent Rights, 

alone or in combination with at least 

one other synthetic peptide for use in 

the prevention and/or treatment of 

adenocarcinomas in humans. For the 

avoidance of doubt, said delivery 

formulation specifically excludes all 

poxviruses, eukaryotic expression 

vectors, and recombinant yeast. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before July 9, 

2007 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Michelle A. Booden, 

PhD., Technology Licensing Specialist, 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 451–

7337; Facsimile: (301) 402–0220; E-mail: 

boodenm@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

technology describes the composition 

and use of nucleic acid sequences that 

encode agonist and one antagonist 

peptide variants of the human 

carcinoembryonic antigen (CEA) 

peptide, including but not limited to 

CAP–1. CEA is an antigen, which is 

expressed on the surface of various 

types of cancer cells. It is capable of 

stimulating a specific cytolytic T cell 

response, as is CAP–1, which is a highly 

immunogenic epitope of CEA. 

Therefore, CAP–1 agonists which are 

capable of eliciting a CEA-specific 

cytolytic T cell response, such as those 

identified by the inventors, may 

represent potential immunogens for use 

as therapeutic agents or vaccines against 

various cancers, and possibly also for 

use against autoimmune diseases. In 

fact, at least one of the agonist peptides 

appears to be more immunogenic than 

the native CAP–1 peptide. CAP–1 

antagonists which are capable of 

reducing or eliminating this T cell 

response, such as the antagonist peptide 

variant identified by the inventors, may 

represent potential agents for use 

against autoimmune responses to CEA 

or to agonist peptide variants thereof. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR Part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR Part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: May 1, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–8888 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

License: Development and 

Commercialization of Therapeutic 

Products for Rheumatoid Arthritis (RA) 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This notice, in accordance 

with 35 U.S.C. § 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), announces that the 

Department of Health and Human 

Services is contemplating the grant of an 

exclusive license to practice the 

inventions embodied in PCT 

Application No. PCT/US01/04125, filed 

February 9, 2001, entitled 

‘‘Identification of a Novel Domain in the 

Tumor Necrosis Factor Receptor Family 

that Mediates Pre-ligand Receptor 

Assembly and Function’’ [E–095–2000/ 

0–PCT–02]; U.S. Patent No. 7,148,061, 

issued December 12, 2006, entitled 

‘‘Identification of Novel Domain in the 

Tumor Necrosis Factor Receptor Family 

that Mediates Pre-ligand Receptor 

Assembly and Function’’ [E–095–2000/ 

0–US–03]; U.S. Patent Application No. 

11/637,272, filed December 12, 2006, 

entitled ‘‘Identification of Novel Domain 

in the Tumor Necrosis Factor Receptor 

Family that Mediates Pre-ligand 

Receptor Assembly and Function’’ [E–

095–2000/0–US–08]; PCT Application 

No. PCT/US06/24909, filed June 26, 

2006, entitled ‘‘A Potential Novel 

Therapeutic Protein Molecule of 

Inflammatory Arthritis Targeting the 

Pre-ligand Assembly Domain (PLAD) of 

Tumor Necrosis Factor Receptor Type 

1’’ [E–095–2000/4–PCT–01]; European 

Patent Application No. 01910476.9, 

filed February 9, 2001, entitled 

‘‘Identification of Novel Domain in the 

Tumor Necrosis Factor Receptor Family 

that Mediates Pre-ligand Receptor 

Assembly and Function’’ [E–095–2000/ 

0–EP–06]; Australian Patent Application 

No. 2001238076, filed on February 9, 

2001, entitled ‘‘Identification of Novel 

Domain in the Tumor Necrosis Factor 

Receptor Family that Mediates PreVerDate Aug<31>2005 18:12 May 08, 2007 Jkt 211001 PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 E:\FR\FM\09MYN1.SGM 09MYN1

sroberts on PROD1PC70 with NOTICES